Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

NCT06529822 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT06529822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06529822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
March 20, 2025
Completion date
June 30, 2034
Enrollment
64 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal adenocarcinoma, melanoma, muscle-invasive bladder carcinoma, non-small cell lung cancer